Baxter Reports Third-Quarter 2025 Results

Core Insights - Baxter International Inc. reported its third-quarter 2025 financial results, highlighting a significant increase in adjusted net income and earnings per share, alongside a strategic focus on continuous improvement and growth initiatives [1][4][11]. Financial Performance - The company reported third-quarter sales from continuing operations of approximately $2.84 billion, representing a 5% increase on a reported basis and a 2% increase on an operational basis [11][12]. - Adjusted net income from continuing operations was $0.69 per diluted share, marking a 41% increase compared to the previous year [4][11]. - U.S. GAAP diluted earnings per share from continuing operations was reported at a loss of $0.10, while adjusted diluted EPS from continuing operations was $0.69 [11][12]. Segment Results - Medical Products & Therapies sales totaled approximately $1.33 billion, declining 1% on both a reported and operational basis, primarily due to reduced sales in the Infusion Therapies & Technologies division [12]. - Healthcare Systems & Technologies sales reached approximately $773 million, increasing 3% on a reported basis and 2% on an operational basis, driven by demand for Care & Connectivity Solutions [12]. - Pharmaceuticals sales amounted to approximately $632 million, reflecting a 7% increase on both a reported and operational basis, supported by strong performance in Drug Compounding and Injectables & Anesthesia products [12]. Strategic Initiatives - The company has launched a new enterprise-wide continuous improvement system aimed at enhancing execution and strengthening future results [2]. - Baxter expects full-year 2025 sales growth from continuing operations to be between 4% to 5% on a reported basis and 1% to 2% on an operational basis, with adjusted earnings from continuing operations projected at $2.35 to $2.40 per diluted share [6][7]. - For the fourth quarter of 2025, Baxter anticipates sales growth from continuing operations of approximately 2% on a reported basis and a decline of about 2% on an operational basis [7].